Allosteric enhancement of the BCR-Abl1 kinase inhibition activity of nilotinib by cobinding of asciminib-Reference-Cited by-同舟云学术

Allosteric enhancement of the BCR-Abl1 kinase inhibition activity of nilotinib by cobinding of asciminib

Published:2022-08 Issue:8 Volume:298 Page:102238
ISSN:0021-9258
Container-title:Journal of Biological Chemistry
language:en
Short-container-title:Journal of Biological Chemistry

Author:

Oruganti Baswanth,Lindahl Erik,Yang Jingmei,Amiri Wahid,Rahimullah Rezwan^ORCID,Friedman Ran^ORCID

Funder

Cancerfonden

Publisher

Elsevier BV

Subject

Cell Biology,Molecular Biology,Biochemistry

Reference73 articles.

1. Therapeutic options for chronic myeloid leukemia: focus on imatinib (Glivec®, GleevecTM);Henkes;Ther. Clin. Risk Manag.,2008

2. Multiple BCR-ABL kinase domain mutations confer polyclonal resistance to the tyrosine kinase inhibitor imatinib (STI571) in chronic phase and blast crisis chronic myeloid leukemia;Shah;Cancer Cell,2002

3. Characterization of AMN107, A selective inhibitor of native and mutant bcr-Abl;Weisberg;Cancer Cell,2005

4. Overriding imatinib resistance with a novel ABL kinase inhibitor;Shah;Science,2004

5. SKI-606, a 4-Anilino-3-quinolinecarbonitrile dual inhibitor of src and Abl kinases, is a potent antiproliferative agent against chronic myelogenous leukemia cells in culture and causes regression of K562 xenografts in nude mice;Golas;Cancer Res.,2003

Cited by 17 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Mechanisms of resistance to tyrosine kinase inhibitor‐targeted therapy and overcoming strategies;MedComm;2024-08-24

2. Beyond IC₅₀- A computational dynamic model of drug resistance in enzyme inhibition treatment;2024-03-26

3. The importance of protein domain mutations in cancer therapy;Heliyon;2024-03

4. Interplay of mutations, alternate mechanisms, and treatment breaks in leukaemia: Understanding and implications studied with stochastic models;Computers in Biology and Medicine;2024-02

5. Synergy and antagonism between azacitidine and FLT3 inhibitors;Computers in Biology and Medicine;2024-02